Remove Clinical Pharmacology Remove Hospitals Remove Vaccine Remove Virus
article thumbnail

New strategy for COVID-19 prophylaxis?

The Pharma Data

Dr. Gunther Hartmann from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn, in cooperation with other members of the cluster of excellence ImmunoSensation2 at the University of Bonn, have shown this in mice. Camouflage protects virus from immune system.

article thumbnail

Article FDA Thank You FDA updates guidance on developing drugs for Covid-19, replacing pandemic-era version

Agency IQ

It also stated that companies should consider whether an investigational product might interact with an administered vaccine for Covid-19. For instance, if the product is intended to prevent hospitalization, patients at a high risk of progression to severe disease should be enrolled in the trial.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in February and March 2024 (Updated)

Agency IQ

Start Date End Date Event Event Type Center 01/10/2024 01/10/2024 FDA Oncology Center of Excellence Presents: Conversations on Cancer: “Bringing Innovation to People Facing Cancer” Webcast Office of the Commissioner 01/26/2024 01/26/2024 Medical Device Sterilization Town Hall: FDA Activities and Challenges in Reducing Reliance on Ethylene Oxide (EtO) (..)

FDA 40
article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Adams, on a first-in-human study of ELU001, a targeted c’dot drug conjugate, in subjects with folate receptor α (frα) overexpressing solid tumours, and Groothuis on the non-clinical pharmacology of the MET-targeting ADC BYON3521. Phil Jones, VP Discovery, RxBiologics, on: ‘Antibody discovery using the Galaxy library platform’.

article thumbnail

BioSpace Movers & Shakers, Oct. 16

The Pharma Data

The award honors McHutchison’s work in developing life-changing and curative therapies for patients with the hepatitis C virus. Trevi Therapeutics – Shashank Rohatagi was named vice president of Pharmacology and Clinical Phrarmacokinetics. Meissa Vaccines – William Daly was named CBO and Keith H.